Immunomodulatory drugs alleviate l‐dopa‐induced dyskinesia in a rat model of Parkinson's disease
Sign Up to like & getrecommendations! Published in 2019 at "Movement Disorders"
DOI: 10.1002/mds.27799
Abstract: Thalidomide and closely related analogues are used clinically for their immunomodulatory and antiangiogenic properties mediated by the inhibition of the proinflammatory cytokine tumor necrosis factor α. Neuroinflammation and angiogenesis contribute to classical neuronal mechanisms underpinning… read more here.
Keywords: parkinson; dopa induced; induced dyskinesia; parkinson disease ... See more keywords
Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on l-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat
Sign Up to like & getrecommendations! Published in 2018 at "Experimental Brain Research"
DOI: 10.1007/s00221-018-5390-4
Abstract: Abstractl-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapy for motor symptoms of Parkinson’s disease (PD); however, with repeated administration, as many as 94% of PD patients develop complications such as l-DOPA-induced dyskinesia. We previously demonstrated that… read more here.
Keywords: 014 dopa; emd 281; ht2a receptor; dopa induced ... See more keywords
Serotonergic targets for the treatment of l-DOPA-induced dyskinesia
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Neural Transmission"
DOI: 10.1007/s00702-017-1837-1
Abstract: Dopamine (DA) replacement therapy with l-3,4-dihydroxyphenylalanine (l-DOPA) continues to be the gold-standard treatment for Parkinson’s disease (PD). Despite clear symptomatic benefit, long-term l-DOPA use often results in the development of l-DOPA-induced dyskinesia (LID), significantly reducing… read more here.
Keywords: targets treatment; treatment; serotonergic targets; dopa ... See more keywords
The striatal cholinergic system in l-dopa-induced dyskinesias
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Neural Transmission"
DOI: 10.1007/s00702-018-1845-9
Abstract: Cholinergic signaling plays a key role in regulating striatal function. The principal source of acetylcholine in the striatum is the cholinergic interneurons which, although low in number, densely arborize to modulate striatal neurotransmission. This modulation… read more here.
Keywords: induced dyskinesias; dopa induced; cholinergic system; cholinergic ... See more keywords
Neuroinflammation in l-DOPA-induced dyskinesia: beyond the immune function
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Neural Transmission"
DOI: 10.1007/s00702-018-1874-4
Abstract: Neuroinflammation is a main component of Parkinson’s disease (PD) neuropathology, where unremitting reactive microglia and microglia-secreted soluble molecules such as cytokines, contribute to the neurodegenerative process as part of an aberrant immune reaction. Besides, pro-inflammatory… read more here.
Keywords: neuroinflammation; neuroinflammation dopa; dopa induced; function ... See more keywords
Effects of histone acetyltransferase inhibitors on l-DOPA-induced dyskinesia in a murine model of Parkinson’s disease
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Neural Transmission"
DOI: 10.1007/s00702-018-1902-4
Abstract: Histone acetylation is a key regulatory factor for gene expression in cells. Modulation of histone acetylation by targeting of histone acetyltransferases (HATs) effectively alters many gene expression profiles and synaptic plasticity in the brain. However,… read more here.
Keywords: dopa induced; induced dyskinesia; parkinson disease;
Metformin Inhibits the Development of l-DOPA-Induced Dyskinesia in a Murine Model of Parkinson’s Disease
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Neurobiology"
DOI: 10.1007/s12035-017-0752-7
Abstract: Metformin is a medication that is widely prescribed for the management of type 2 diabetes. In addition to its anti-diabetic uses, metformin has been proposed as a therapeutically effective drug candidate in various central nervous… read more here.
Keywords: treatment; metformin; dopa; dopa induced ... See more keywords
Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Sign Up to like & getrecommendations! Published in 2021 at "Neurotoxicity research"
DOI: 10.1007/s12640-021-00345-x
Abstract: Interferon-γ (IFN-γ) is a proinflammatory cytokine that activates glial cells. IFN-γ is increased in the plasma and brain of Parkinson's disease patients, suggesting its potential role in the disease. We investigated whether the IFN-γ deficiency… read more here.
Keywords: ifn mice; ifn; disease; dopa induced ... See more keywords
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements
Sign Up to like & getrecommendations! Published in 2018 at "Behavioural Brain Research"
DOI: 10.1016/j.bbr.2018.03.002
Abstract: HighlightsSelegiline extends l‐Dopa‐induced shortened on time in hemi‐parkinsonian rats.Selegiline does not exacerbate l‐Dopa‐induced dyskinesia in hemi‐parkinsonian rats.Selegiline does not alter PDy and Arc mRNA expression in the lesioned striatum. ABSTRACT 3,4‐Dihydroxy‐l‐phenylalanine (l‐Dopa) remains the most… read more here.
Keywords: time without; time; dopa induced; lesioned rats ... See more keywords
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats
Sign Up to like & getrecommendations! Published in 2017 at "Experimental Neurology"
DOI: 10.1016/j.expneurol.2017.07.017
Abstract: In addition to its role in neuronal survival, the brain neurotrophic factor (BDNF) has been shown to influence serotonin transmission and synaptic plasticity, events strongly implicated in the appearance of l-DOPA-induced dyskinesia (LID), a motor… read more here.
Keywords: ohda lesioned; dopa; expression; dopa induced ... See more keywords
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia
Sign Up to like & getrecommendations! Published in 2018 at "Neuropharmacology"
DOI: 10.1016/j.neuropharm.2018.09.005
Abstract: ABSTRACT Dopamine (DA)‐replacement therapy utilizing l‐DOPA is the gold standard symptomatic treatment for Parkinson's disease (PD). A critical complication of this therapy is the development of l‐DOPA‐induced dyskinesia (LID). The endogenous opioid peptides, including enkephalins… read more here.
Keywords: mmp 2200; mmp; dopa induced; receptor ... See more keywords